Entry into a Material Definitive Agreement

On November 26, 2019, OncoSec Medical Incorporated (the "Company") reported that it has entered into an (a) amendment, dated November 26, 2019 to the Stock Purchase Agreement and the Stockholder Agreement, each between the Company and Grand Decade Developments Limited, a British Virgin Islands limited company and a wholly owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited ("CGP), dated as of October 10, 2019 (the "CGP Amendment") and (b) amendment, dated November 26, 2019, to the Stock Purchase Agreement between the Company and Sirtex Medical US Holdings, Inc., an affiliate of CGP ("Sirtex"), dated as of October 10, 2019 (the "Sirtex Amendment" and, collectively with the CGP Amendment, the "Amendments") (Filing, 8-K, OncoSec Medical, NOV 26, 2019, View Source [SID1234551706]). The Amendments provide for, among other things, the removal of proposals from the Company’s current preliminary proxy statement for an increase in the number of the Company’s authorized outstanding shares of common stock as well as the corporate opportunity waiver. The Company’s board of directors passed resolutions to approve the corporate opportunity waiver pursuant to NRS 78.070(8).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!